X XERIS BIOPHARMA HOLDINGS INC
| Market Cap | $1.04B |
| P/E Ratio | — |
| Forward P/E | 16.30 |
| Dividend Yield | — |
| Beta | 0.99 |
| 52W Range | $3.95 - $9.90 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $1.05M | 133,416 | Add 0.17% |
Insider Trading
| Insider Name of the company insider who made the trade 17 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Hecht BethSee Remarks | Sale | 16,667 | $5.99 | $99.86K | 01 Apr 2026 | 01 Apr 2026 |
| James Aloysius BradyDirector | Sale | 10,834 | $5.54 | $60.04K | 30 Mar 2026 | 01 Apr 2026 |
| Hecht BethSee Remarks | Sale | 16,567 | $6.24 | $103.38K | 02 Mar 2026 | 04 Mar 2026 |
| Hecht BethSee Remarks | Sale | 100 | $7.06 | $706 | 02 Mar 2026 | 04 Mar 2026 |
| Hecht BethSee Remarks | Sale | 16,667 | $7.45 | $124.15K | 02 Feb 2026 | 02 Feb 2026 |
| Beth HechtChief Legal Officer and Corporate Secretary | Sale | 16,667 | $7.45 | $124.15K | 02 Feb 2026 | 02 Feb 2026 |
| McCulloch KevinSee Remarks | Sale | 15,000 | $8.00 | $120.00K | 08 Jan 2026 | 09 Jan 2026 |
| Shannon John Patrick JrSee Remarks | Sale | 24,907 | $7.08 | $176.26K | 05 Jan 2026 | 06 Jan 2026 |
| John Patrick Shannon JrChief Executive Officer and Director | Sale | 24,907 | $7.08 | $176.26K | 05 Jan 2026 | 06 Jan 2026 |
| Hecht BethSee Remarks | Sale | 16,667 | $7.43 | $123.78K | 02 Jan 2026 | 05 Jan 2026 |
| Beth HechtChief Legal Officer and Corporate Secretary | Sale | 16,667 | $7.43 | $123.78K | 02 Jan 2026 | 05 Jan 2026 |
| JOHNSON JOHN | Sale | 135,400 | $7.22 | $977.02K | 19 Dec 2025 | 19 Dec 2025 |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Sale | 15,000 | $7.09 | $106.41K | 12 Dec 2025 | 15 Dec 2025 |
| Hecht BethSee Remarks | Sale | 16,667 | $7.01 | $116.78K | 01 Dec 2025 | 02 Dec 2025 |
| Beth HechtChief Legal Officer and Corporate Secretary | Sale | 16,667 | $7.01 | $116.78K | 01 Dec 2025 | 02 Dec 2025 |
| Shannon John Patrick JrSee Remarks | Sale | 23,242 | $7.46 | $173.40K | 13 Nov 2025 | 17 Nov 2025 |
| Hecht BethSee Remarks | Sale | 16,667 | $7.40 | $123.30K | 11 Nov 2025 | 13 Nov 2025 |
Frequently Asked Questions
What is XERS stock price today?
XERIS BIOPHARMA HOLDINGS INC (XERS) is currently trading at $6.04. The stock has a 52-week range of $3.95 to $9.90 and a market capitalization of $1.04B.
Is XERS a good stock to buy in 2026?
XERIS BIOPHARMA HOLDINGS INC has a P/E ratio of N/A (forward P/E: 16.3), a dividend yield of none, and 1-year performance of +23.8%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling XERS stock?
There have been 17 insider transactions for XERS in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has XERS stock performed over the past year?
XERIS BIOPHARMA HOLDINGS INC (XERS) has returned +23.8% over the past 12 months. The stock traded between $3.95 and $9.90 during this period, and is currently at $6.04.
Which hedge funds own XERS (XERIS BIOPHARMA HOLDINGS INC)?
1 tracked hedge funds currently hold XERS in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is XERS's market cap and valuation?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a market capitalization of $1.04B. The trailing P/E ratio is N/A and forward P/E is 16.3. The stock is classified in the Healthcare sector.
What is XERS's revenue and profitability?
XERIS BIOPHARMA HOLDINGS INC reported revenue of $291.84M with net income of $554.00K and a profit margin of 0.00%. The stock has a beta of 0.99.
What sector is XERS in and who are its biggest institutional holders?
XERIS BIOPHARMA HOLDINGS INC (XERS) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.